Adding Pembrolizumab to Standard Care Ups Event-Free Survival in Head, Neck Cancer

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on June 27, 2025.

via HealthDay

FRIDAY, June 27, 2025 -- For patients with locally advanced head and neck squamous cell carcinoma (HNSCC), the addition of neoadjuvant and adjuvant pembrolizumab to standard care significantly improves event-free survival, according to a study published online June 18 in the New England Journal of Medicine.

Ravindra Uppaluri, M.D., Ph.D., from Brigham and Women's Hospital in Boston, and colleagues conducted a phase-3, open-label trial involving patients with locally advanced HNSCC who were randomly assigned to receive two cycles of neoadjuvant pembrolizumab and 15 cycles of adjuvant pembrolizumab in addition to standard care (pembrolizumab group) or standard care alone, comprising surgery and adjuvant radiotherapy with or without concomitant cisplatin (control group; 363 and 351 patients, respectively).

In each group, surgery was completed in approximately 88 percent of the participants. The median follow-up was 38.3 months at the first interim analysis. The researchers found that event-free survival at 36 months was 59.8 and 45.9 percent in the pembrolizumab and control groups (hazard ratio [HR] for progression, recurrence, or death, 0.66) among participants whose tumors expressed programmed death ligand 1 (PD-L1) with a combined positive score (CPS) of 10 or more; 58.2 and 44.9 percent, respectively (HR, 0.70) for participants whose tumors expressed PD-L1 with a CPS of 1 or more; and 57.6 and 46.4 percent, respectively (HR, 0.73) among all participants. Grade-3 or higher treatment-related adverse events occurred in 44.6 and 42.9 percent of participants in the pembrolizumab and control groups, respectively.

"Results for overall survival were not mature at the first prespecified interim analysis; additional follow-up is ongoing," the authors write.

The study was funded by Merck, the manufacturer of pembrolizumab.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-06-28 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords